Search
Licofelone
go.drugbank.com/drugs/DB04725ExperimentalDeveloped by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inf...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsLysergic acid diethylamide
go.drugbank.com/drugs/DB04829IllicitInvestigationalDebate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a mani...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesBiricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitorsNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesFlibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a si...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsClevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTelmapitant
go.drugbank.com/drugs/DB20768ExperimentalThe usage of the INN stem '-pitant' in the name indicates that Telmapitant is a neurokinin NK1 (substance P) receptor antagonist. Telmapitant has a monoisotopic molecular weight of 515.16 Da.